




























In Person Clinical Trials

 <p>DRUG</p>	<p><u>VERTEX VX-880</u> AGES 18-65 2 EPISODES OF SEVERE HYPOGLYCEMIA T1D AT LEAST 5 YEARS LOCATION: MA</p>	
 <p>DRUG</p>	<p><u>VERTEX VX-264</u> AGES 18-65 T1D FOR AT LEAST 5 YEARS LOCATION: MA</p>	
 <p>DEVICE</p>	<p><u>PRECISION II STUDY</u> AGES 18-75 T1D AT LEAST 3 MONTHS LOCATION: MA</p>	
 <p>DEVICE</p>	<p><u>STEADiSET 7 DAY INFUSION SET</u> AGES 18+ USING TANDEM CONTROL IQ COMPENSATION UP TO \$1240 LOCATION: MA</p>	
 <p>OBSERVATIONAL</p>	<p><u>JOSLIN HEART AND KIDNEY</u> AGES 25-65 DIAGNOSED BEFORE 41 NORMAL/MODERATELY DECREASED KIDNEY FUNCTION LOCATION: MA</p>	
 <p>DRUG</p>	<p><u>PERL-FENO STUDY</u> AGES 18-70 T1D AT LEAST 8 YEARS EARLY/MODERATE DKD W/ RISK OF ESKD LOCATION: MA</p>	

 OBSERVATIONAL	<p align="center"><u>PROMISE</u> PREGNANT WOMEN/BIOLOGICAL FATHERS OF OFFSPRING W/ 1ST DEGREE T1D RELATIVE LOCATION: MA</p>	
 DRUG	<p align="center"><u>EFFECTS OF KETOSIS ON BRAIN FUNCTION</u> AGES 18-40 T1D AT LEAST 1 YEAR WITH A1C 6.5-9% USE OF CGM AND INSULIN PUMP LOCATION: MA</p>	
 OBSERVATIONAL	<p align="center"><u>BONE HEALTH IN T1D YOUTH</u> AGES 6-20 WITH T1D AND WITHOUT T1D EARN UP TO \$300 LOCATION: MA</p>	
 DEVICE	<p align="center"><u>TANGO</u> PARTICIPANTS OVER 65 MDI OR PUMP LOCATION: MA</p>	
 DEVICE	<p align="center"><u>CIAO</u> AGES 18-35 or 65+ MULTIPLE DAILY INJECTIONS LOCATION: MA</p>	
 BEHAVIORAL	<p align="center"><u>EATING DISORDER PREVENTION PROGRAM</u> AGES 14-35 T1D AT LEAST 1 YEAR W/ BODY IMAGE CONCERNS LOCATION: MA</p>	
 BEHAVIORAL	<p align="center"><u>VERY LOW CARB DIET STUDY</u> AGES 18-40 T1D AT LEAST 1 YEAR WITH A1C 6.5-9% LOCATION: MA</p>	



DEVICE

EVERSENSE
PARTICIPANTS OVER 18
NOT CURRENTLY USING CGM
LOCATION: VT



OBSERVATIONAL

IMMUNE FUNCTION
ALL AGES T1DS AND/OR
FAMILY MEMBERS OF T1DS
EARN \$20
LOCAL LAB



Virtual Clinical Trials



SURVEY

UNIVERSITY OF OREGON STUDY
T1D AT LEAST 3 MONTHS
USING CGM
VIRTUAL



BEHAVIORAL

USF MINDFULNESS APP
AGES 12-19
T1D AT LEAST 6 MONTHS
EARN \$80
VIRTUAL




BEHAVIORAL

CGM SHARING IN OLDER ADULTS
AGES 60+
A1C 7.5-11%
VIRTUAL



PREVENTION













TRIALNET
DIRECT RELATIVES OF
T1DS AGES 2-45
VIRTUAL OR TRIALNET CENTER













DEVICE

EXTENDED BOLUS CLOSED LOOP
AGES 13-18
T1D AT LEAST 1 YEAR
USING CONTROL IQ
VIRTUAL



 <p>SURVEY</p>	<p><u>T1D EXCHANGE REGISTRY</u> INDIVIDUALS WITH T1D AND/OR THEIR CAREGIVERS</p> <p>VIRTUAL</p>	
 <p>BEHAVIORAL</p>	<p><u>T1D BODY ACCEPTANCE PROJECT</u> FEMALES AGES 15-30 W/ BODY IMAGE CONCERNS AND/OR DISORGANIZED EATING EARN \$110</p> <p>VIRTUAL/MA</p>	
 <p>BEHAVIORAL</p>	<p><u>TELE-MED COGNITIVE BEHAVIOR THERAPY</u> AGES 18-35 T1D AT LEAST 6 MONTHS WITH ANXIETY OR DEPRESSION</p> <p>VIRTUAL</p>	
 <p>DEVICE</p>	<p><u>FREESTYLE LIBRE 2 OR 3</u> AGES 2-30 NOT CURRENTLY USING LIBRE 2 OR 3</p> <p>VIRTUAL</p>	
 <p>BEHAVIORAL</p>	<p><u>BEAD-T1D</u> AGES 12-21 PUBLIC PAYER INSURANCE</p> <p>VIRTUAL</p>	
 <p>BEHAVIORAL</p>	<p><u>T1DAL</u> AGES 13-18 T1D AT LEAST 6 MONTHS</p> <p>VIRTUAL</p>	

Newly Diagnosed Clinical Trials

 DRUG	<p><u>JAKPOT-T1D</u> AGES 12-35 T1D LESS THAN 100 DAYS, A1C <10% LOCATION: MA</p>	
 DRUG	<p><u>T1D RELAY</u> AGES 8-45 T1D LESS THAN 100 DAYS LOCATION: MA</p>	
 DRUG	<p><u>STOP-T1D STUDY</u> AGES 6-35 IN STAGE 2 DIABETES LOCATION: MA</p>	
 DRUG	<p><u>DESIGNATE</u> AGES 18-45 WITHIN 18 MONTHS OF DIAGNOSIS LOCATION: MA</p>	
 DRUG	<p><u>DIAGNODE-3</u> AGES 12-28 WITHIN 6 MONTHS OF DIAGNOSIS LOCATION: MA</p>	

Trial Tool and CTEV Contact Info

Clinical Trials Connection Tool
Match to a Clinical Trial in 60 Seconds



Breakthrough T1D Greater New England
Clinical Trial Education Volunteers
AmandaJGilchrist@gmail.com and Kristin.Neff@gmail.com